Future directions in the treatment of Parkinson's disease.
Identifieur interne : 002341 ( PubMed/Curation ); précédent : 002340; suivant : 002342Future directions in the treatment of Parkinson's disease.
Auteurs : Anthony H V. Schapira [Royaume-Uni]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
- Cholinergic Antagonists (therapeutic use), Coenzymes (therapeutic use), Dopamine Agonists (therapeutic use), Drug Therapy (trends), Forecasting, Humans, Intercellular Signaling Peptides and Proteins (therapeutic use), Monoamine Oxidase Inhibitors (therapeutic use), Parkinson Disease (drug therapy), Ubiquinone (analogs & derivatives), Ubiquinone (therapeutic use).
- MESH :
- chemical , analogs & derivatives : Ubiquinone.
- chemical , therapeutic use : Cholinergic Antagonists, Coenzymes, Dopamine Agonists, Intercellular Signaling Peptides and Proteins, Monoamine Oxidase Inhibitors, Ubiquinone.
- drug therapy : Parkinson Disease.
- trends : Drug Therapy.
- Forecasting, Humans.
Abstract
The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2-adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late-stage development for PD and offer benefit for motor symptoms and motor complications.
DOI: 10.1002/mds.21679
PubMed: 18175401
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002341
Links to Exploration step
pubmed:18175401Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Future directions in the treatment of Parkinson's disease.</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H V" last="Schapira">Anthony H V. Schapira</name><affiliation wicri:level="1"><nlm:affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, UK. a.schapira@medsch.ucl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:18175401</idno><idno type="pmid">18175401</idno><idno type="doi">10.1002/mds.21679</idno><idno type="wicri:Area/PubMed/Corpus">002341</idno><idno type="wicri:Area/PubMed/Curation">002341</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Future directions in the treatment of Parkinson's disease.</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H V" last="Schapira">Anthony H V. Schapira</name><affiliation wicri:level="1"><nlm:affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, UK. a.schapira@medsch.ucl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London</wicri:regionArea></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cholinergic Antagonists (therapeutic use)</term><term>Coenzymes (therapeutic use)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Therapy (trends)</term><term>Forecasting</term><term>Humans</term><term>Intercellular Signaling Peptides and Proteins (therapeutic use)</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Ubiquinone (analogs & derivatives)</term><term>Ubiquinone (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ubiquinone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cholinergic Antagonists</term><term>Coenzymes</term><term>Dopamine Agonists</term><term>Intercellular Signaling Peptides and Proteins</term><term>Monoamine Oxidase Inhibitors</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Therapy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Forecasting</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2-adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late-stage development for PD and offer benefit for motor symptoms and motor complications.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18175401</PMID><DateCreated><Year>2008</Year><Month>01</Month><Day>04</Day></DateCreated><DateCompleted><Year>2008</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>22 Suppl 17</Volume><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Future directions in the treatment of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>S385-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.21679</ELocationID><Abstract><AbstractText>The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2-adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late-stage development for PD and offer benefit for motor symptoms and motor complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schapira</LastName><ForeName>Anthony H V</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, UK. a.schapira@medsch.ucl.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018680">Cholinergic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003067">Coenzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>1339-63-5</RegistryNumber><NameOfSubstance UI="D014451">Ubiquinone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EJ27X76M46</RegistryNumber><NameOfSubstance UI="C024989">coenzyme Q10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018680">Cholinergic Antagonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003067">Coenzymes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004358">Drug Therapy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000639">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005544">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D036341">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008996">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014451">Ubiquinone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>85</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18175401</ArticleId><ArticleId IdType="doi">10.1002/mds.21679</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002341 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002341 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:18175401
|texte= Future directions in the treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18175401" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |